JGL d.d. company profile
JGL was founded in Rijeka in 1991 as the first private pharmaceutical joint-stock company. Today, it is an international pharmaceutical company aimed at developing and manufacturing drugs in target therapeutic areas, with a focus on the senses. With the aim of improving the quality of life by taking care of human health, JGL offers products in nearly all technological forms and different legislative categories and operates in around 40 foreign markets, primarily in the CIS (Russia, Ukraine, Kazakhstan) and SEE markets.
The propulsive and sustainable company growth is based on continuous investment in employee knowledge, strategy development and the launch of new products, as well as the strategy of expansion into new markets. JGL intends to exploit its key competencies by focusing on the development and production of sterile pharmaceutical forms for otorhinolaryngology and ophthalmology indications. Today, the company’s portfolio consists of nearly 160 brands, 460 products and 1360 variations, among which Aqua Maris, Meralys, Normia, Lactogyn, Dramina and Vizol S stand out in particular.
By keeping up with trends in the pharmaceutical industry, JGL boasts a flexible and modern production, compliant with regulatory (GMP) and internal quality demands. Out of approximately 1,000 employees, 76 percent are women, 70 percent have a university degree, and the average age of employees is 37, which makes for a highly dynamic, modern and entrepreneurial company environment.
From day one, the company has been developing with very high growth rates – 22 percent on average. JGL group ranks third within the national pharmaceutical industry, with the revenue of € 107 million in 2014. The export share in the overall company revenue for the year 2014 amounted to 72.50 percent. The company plans to enter into another 20 markets by 2020, focusing on the fast-growing markets and key global regions - the Middle East, Western Europe, the USA, South America, China and Vietnam.
Thanks to the new facility, JGL Pharma Valley complex, this pharmaceutical company is now ranked among the leading manufacturers of sterile pharmaceutical forms – drops, sprays and BoV – in the European Union. The project has two key goals – to secure the preconditions and capacities in development, production and storage for the realisation of the company's long-term growth plans, and to bring all production and technological locations in one place. Furthermore, and considering that the company is focused on the development and production of drugs for the senses, additional capacities in the existing plants for sterile solutions and the new plant for aerosols and equipping of solutions will certainly help the company to realise its strategy of further improving the position of its key brands on the global health market.
You can read more about the JGL HERE